ZL0516

ZL0516 is a small molecule epigenetic modulator that acts as a potent and specific inhibitor of bromodomain-containing protein 4 (BRD4). Developed for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, ZL0516 works by disrupting the interaction between BRD4 and acetylated histone lysine residues. This inhibition prevents the stabilization of NFκB binding on inflammatory gene promoters and suppresses the activation of RNA polymerase II, thereby blocking the pathological BRD4-NFκB signaling pathway. In preclinical animal models, ZL0516 has demonstrated the ability to reduce mucosal inflammation, restore tissue architecture, and decrease the expression of key inflammatory cytokines such as TNFα, IL-6, IL-17A, and IL-1β.